Inferring causal genomic alterations in breast cancer using gene expression data
- Linh M Tran†1, 2,
- Bin Zhang†1, 2Email author,
- Zhan Zhang2,
- Chunsheng Zhang2,
- Tao Xie2,
- John R Lamb2,
- Hongyue Dai2,
- Eric E Schadt1, 2, 3Email author and
- Jun Zhu1, 2Email author
© Tran et al; licensee BioMed Central Ltd. 2011
Received: 14 March 2011
Accepted: 1 August 2011
Published: 1 August 2011
One of the primary objectives in cancer research is to identify causal genomic alterations, such as somatic copy number variation (CNV) and somatic mutations, during tumor development. Many valuable studies lack genomic data to detect CNV; therefore, methods that are able to infer CNVs from gene expression data would help maximize the value of these studies.
We developed a framework for identifying recurrent regions of CNV and distinguishing the cancer driver genes from the passenger genes in the regions. By inferring CNV regions across many datasets we were able to identify 109 recurrent amplified/deleted CNV regions. Many of these regions are enriched for genes involved in many important processes associated with tumorigenesis and cancer progression. Genes in these recurrent CNV regions were then examined in the context of gene regulatory networks to prioritize putative cancer driver genes. The cancer driver genes uncovered by the framework include not only well-known oncogenes but also a number of novel cancer susceptibility genes validated via siRNA experiments.
To our knowledge, this is the first effort to systematically identify and validate drivers for expression based CNV regions in breast cancer. The framework where the wavelet analysis of copy number alteration based on expression coupled with the gene regulatory network analysis, provides a blueprint for leveraging genomic data to identify key regulatory components and gene targets. This integrative approach can be applied to many other large-scale gene expression studies and other novel types of cancer data such as next-generation sequencing based expression (RNA-Seq) as well as CNV data.
Keywordsbreast cancer copy number variation gene regulatory networks oncogenes
Tumors arise from the activation of oncogenes along with the inactivation of tumor suppressor genes via somatic gene mutations or copy number variation (CNV). Identification of the genetic/genomic changes that drive biological processes associated with cancer onset or progression assists in the development of therapeutics targeting the affected proteins or their downstream consequences[1–4]. Although extensive gene expression studies have been conducted for identifying tumor signature genes associated with poor outcome[5, 6], the reproducibility of these signatures is low[7, 8], posing a major challenge for identifying the causal genetic/genomic variations.
Genome-wide DNA copy number variation (CNV) has been increasingly used for identifying biomarkers and targets in cancer research[9–11]. Unfortunately, the CGH, SNP genotype, and DNA sequencing data typically used to detect CNV are not available for many published, large-scale studies. Therefore, the development of methods to infer CNV from non-genetic data collected in these studies would serve to enhance their scientific value. Strong correlations between CNV and gene expression have been observed[11, 12] and initially suggested the possibility of detecting CNV directly from gene expression data. Recently, the Analysis of Copy number alteration by Expression (ACE) algorithm was developed to identify amplified or deleted chromosome regions based on gene expression data. While this approach demonstrated the utility of leveraging expression data to identify candidate CNV regions and genes whose expressions might be affected by the candidate CNV, the identified regions were often large and harbored many genes. Furthermore, no objective mechanism was employed to distinguish cancer driver genes from passenger genes within a putative CNV region.
Here we describe a novel Wavelet based Analysis of Copy number alteration by Expression (WACE) algorithm and combine it with Bayesian networks via a key driver analysis to provide a systematic and unified approach for distinguishing cancer driver genes from passenger genes residing in inferred copy number variation sites.
We collected four independent breast cancer datasets, NKI, Wang, Miller, and Christos. NKI samples were profiled on the Agilent Human 25 K platform comprised of 24,496 non-control oligonucletoide probes while the other studies were carried out using the Affymetrix HG133A platform, compromised of 22,282 probe sets. Each of the four microarray datasets was adjusted for estrogen and progesterone receptor (ER/PR) status as well as age to avoid their influence. The data were fit using a robust linear regression model (rlm function from R statistical package), and the residuals with respect to the model fit were carried forward in all subsequence analyses as the gene expression traits. In all analyses except ACE, the expression of individual gene/probe was used. In the subsequent analysis, for a gene with multiple probes we used the average expression profile to represent its expression so as to eliminate the weight effect due to multiple data points on a single location.
We also downloaded the gene expression and aCGH data from the Stanford University Breast Cancer Study http://smd.stanford.edu/. Again the expression profiles of multiple probes representing the same gene were consolidated by average. The expression and aCGH data were adjusted for array batch, ER/PR status and age to avoid their influence.
A Unified Framework for Expression based CNV Inference and Causal Gene Identification
Wavelet based Analysis of Copy number alteration by Expression (WACE)
Distinguishing cancer driver genes from passenger genes via reconstruction of Bayesian networks
where eq. (1) represents G independent of C1 and C2, eq.s (2) - (4) represent G regulated by C1 , C2, both C1 and C2, respectively. As there are many other potential genes or factors that can affect the expression levels of gene G, the models eq. (1) - (4) are needed to condition on all other such factors. Thus, the model selection process is equivalent to a Bayesian network reconstruction process, which will be discussed subsequently.
Bayesian network is a probabilistic representation of the gene regulatory network and has shown superior performance in integrating genetic data into gene causal networks predictive of complex phenotypes[20–25]. 6,312, 6,349, 6,268 and 5,802 differentially regulated genes for NKI, Wang, Miller, and Christos, respectively, were selected as input into a Bayesian network reconstruction software program based on a previously described algorithm. Markov Chain Monte Carlo (MCMC) simulation was then employed to identify the most plausible structures. For each seed, 15*n2 iterations of MCMC were run on average, where n is the number of nodes. The Bayesian Information Criterion (BIC) scores were used as the optimization criteria. One thousand Bayesian networks were reconstructed using different random seeds to start the reconstruction process. From the resulting set of 1000 networks generated by this process, edges that appeared in greater than 30% of the networks were used to define a consensus network. The cutoff of 30% was based on a simulation study. When summarizing 1000 constructed structures from random seeds, the histogram of the number of link occurrences among 1000 structures shows a bimodal distribution, where 30% is the best value to separate the two modes and also has the best recall-precision tradeoff . Edges in this consensus network were removed if 1) the edge was involved in a loop, and 2) the edge was the most weakly supported of all edges making up the loop.
Key Driver Analysis (KDA)
One primary goal of gene network analysis is to identify key regulatory components, or key drivers, of sub-networks with respect to varying biological contexts [25, 27]. The KDA takes as input a set of genes (G) and a gene causal (directed) network N. The objective is to identify the key regulators for the gene sets with respect to the given network. Candidate drivers are identified as follows. We first compute the size of the h-layer neighborhood (HLN) for each node. The range of h is from 1 to the diameter of the network N. Specifically, for a given node g, the size of its HLN is the number of its downstream nodes that are within h edges away from g. For the given network N, let μ be an array of the sizes of HLNs and d be an array of the out-degrees for all the nodes. The nodes are nominated as candidate drivers if their sizes of their HLN are greater than , where is the mean of μ is and σ(μ) is the standard deviation of μ. The candidate drivers without any parent node (i.e., root nodes) are nominated as global drivers while the rest are local regulators. Let be the mean of d and σ(d) be the standard deviation of d. We also promote hub nodes as global drivers, i.e., the nodes with out-degrees above are designated as global drivers. These criteria identify genes with number of downstream nodes or number of outlinks significantly above the average.
By definition, each driver modulates a set of genes, i.e., its downstream nodes. Previous work has shown that a gene's function can be predicted by its neighbor genes in networks. Moreover, a series of validation experiments show that the downstream nodes of a driver predicted by Bayesian networks significantly overlap with its knockout signature.
siRNA Screen and Cell Viability Assays
Cell lines and siRNA library
Four different breast cancer cell lines, ER-positive MCF7 and ZR-75-1; and ER-negative MDA-MB-231and MDA-MB-468, were obtained from the American Type Culture Collection, Rockville, MD (Catalogue numbers HTB-22, HTB-26, HTB-132 and CRL-1500, respectively). The siRNA library targets ~2,400 unique human genes, with three siRNAs per gene, as described previously. The library represents genes comprising kinases, membrane proteins, enzymes, components of major cellular pathways including cell cycle, transcription regulation, and signal transduction, etc. . siRNA sequences were designed with an algorithm developed to increase efficiency of the siRNAs for silencing while minimizing their off-target effects . siRNAs were ordered from Sigma-Proligo (The Woodlands, TX).
siRNA screen and cell viability assays
siRNA screens were performed as described previously and cells were transfected using RNAiMAX (Invitrogen, Carlsbad, CA). Cell viability assay was determined using AlamarBlue reagent (BioSource International, Camarillo, CA). The fluorescence signal was corrected for background (no cells). Cell growth was expressed as % viability relative to the median value of wells transfected with an siRNA to Luciferase.
As detailed in the Materials and Methods, the proposed unified framework for expression based CNV inference and causal gene identification is comprised of three major components, wavelet based CNV inference, causal network construction and key driver identification.
Performance Comparison of WACE and GACE
The original ACE approach for identifying amplified or deleted chromosome regions used the simple Gaussian transform to smooth the data and then identified the significantly abnormal regions comprised of over- or under-expressed genes via a permutation test. Although this approach, named GACE, was able to narrow down genes whose expression might be affected by the local CNV, it often systematically overestimated the size of the identified regions which were typically re-arrangements of small sequences. We improved GACE by introducing: i) a wavelet based smoothing technique and ii) a new statistical method for assessing significance of putative CNV regions. Wavelet transform is a more sophisticated filtering technique and has become a cutting-edge technology in signal and image processing because of its superior ability to accurately deconstruct and reconstruct finite, non-periodic and/or non-stationary signals. This led to a wavelet-based ACE algorithm (WACE) to efficiently and accurately narrow down amplified/deleted regions of the genome in cancer samples.
To access the performance of WACE, first we compared it with the existing method GACE based on a previously published breast cancer study , which consisted of gene expression and aCGH data, as well as clinical data relating to tumor progression (referred to here as BCS1). A detailed comparison is described in Additional File 1, WACE and GACE Comparison (Section 2.1). Figure S4 to S6 in Additional File 1 illustrated the comparison results between two methods based on (i) the correlation coefficient between the expression- and aCGH-based NS profiles, and (ii) re-identifying CNVs based on gene expression, respectively. Here we summarize the findings: (i) WACE uncovered almost three times as many expression ICNV regions overlapping with the aCGH ICNV regions compared to GACE, and (ii) these two sets of regions identified by WACE were better correlated with each other than those identified by GACE.
We also verified the cis-effect of CNV on gene expression by considering the correlation between the aCGH and gene expression data of each gene in BCS1. The expression of the genes located in the overlapped CNV regions was highly correlated to the corresponding aCGH data. For instance, WACE identified in both expression and aCGH data a DNA amplification region at 20q13, and the gene expression and aCGH NS profiles were highly correlated (r = 0.55).
Amplified regions associated with poor outcome affect cell cycle
We applied WACE to the aforementioned four breast cancer microarray studies [6, 8, 14, 15] to infer CNV regions associated with metastasis. Each dataset was independently analyzed by WACE and the identified regions were then aligned to locate the recurrent regions of ICNVs. To calculate the ES's for each dataset, the samples were classified into two groups, the patients with metastases within 5 years and those with no metastasis after more than 5 years of follow-up.
The inferred recurrent regions of CNV in the four breast cancer datasets.
ECT2, PIK3CA, PSMD2, CLCN2, POLR2H
MAP3K11, ADRBK1, RPS6KB2, LRP5, CPT1A
POLR2C, KIFC3, CSNK2A2, GOT2, CDH5, PSKH1, PSMB10, VPS4A,
TPX2, APBA2BP, E2F1, EIF2S2, AHCY, GSS, PROCR, RBM39, SCAND1, DLGAP4, GHRH, BLCAP
These regions were tested for gene enrichment using the gene ontology (GO) categories, KEGG, Panther, and GeneGo pathways. The most enriched categories include nucleosome assembly (P < 7.24E-22), chromatin assembly (P < 1.02E-20), systemic lupus erythematosus (P < 9.03E-18), chromatin assembly or disassembly (P < 4.57E-17), DNA packaging (P < 1.29E-16) and protein-DNA complex assembly (P < 1.92E-11). Cell cycle and cholesterol biosynthetic process pathways are also enriched in the regions. All the enriched categories are shown Additional File 1, Table S3.
ICNV regions versus aCGH based regions
We further examined to what extent the recurrent CNVs inferred by gene expression reflect the recurrent CNVs based on an independent aCGH data in BCS1. To ensure an objective comparison, we used a popular CNV detection method, the circular binary segmentation (CBS) algorithm (implemented in the DNAcopy package from Bioconductor) on the aCGH data. Forty six or 68.7% of the 67 CBS based aCGH CNV regions in BCS1 significantly (gene-based FET P = 3.1e-13) overlapped with the 109 recurrent ICNV regions detected by WACE on the four gene expression studies. The overlapped regions on chromosome 8, 11, and 20 have been previously identified via analysis of CGH arrays applied to breast cancer tumors . These results demonstrate a good correspondence between the inferred CNV regions and the experimental results and thus confirm the accuracy of WACE.
Breast Cancer Gene Regulatory Networks
Four whole-genome gene regulatory networks were first constructed by the Bayesian network reconstruction method  for the aforementioned four breast cancer studies (NKI, Christos, Miller, and Wang) and then were combined by union of directed links to form a single network, which consisted of 10,118 genes and 20,732 directed links. Previous works have shown that genes controlling many other genes in gene regulatory networks are more likely regulatory genes regulating their downstream genes[24, 25, 27]. The top 5 genes with the most out links are ARF1, FOXA1, ESR1, HIF1A and UBE2C. ARF1 is involved in the activation of the PI3K/AKT pathways which regulate cell survival and proliferation. HIF1A plays an essential role in cellular and systemic homeostatic response to hypoxia was recently found to regulate the metastasis of breast tumor to lung. FOXA1, ESR1 and UBE2C, are known as breast cancer prognosis biomarkers. The global features of the combined network are described in detail in Additional File 1, Properties of Breast Cancer Bayesian Networks (Section 3).
Key Driver Analysis
We assume that the cancer driver genes have broad impacts on global gene expression while passenger genes have small impacts . To quantify impacts of genes residing in the recurrent ICNVs detected across multiple data sets, we count numbers of downstream genes that are regulated by each candidate gene locally or globally in the combined network. Genes are grouped into global drivers, local drivers and passengers according to the rank of these numbers (see Methods for details). In the key driver analysis, we focus on the genes residing in amplified regions which are regarded as a hallmark of dominant cancer driver genes.
For the genes in the recurrent regions of amplification (RR Gain), we identified 44 global drivers and 24 local drivers. Known breast cancer susceptibility genes like TPX2, AURKA, TK1 and BIRC5 are among the top 7 global drivers (the other 3 top drivers are GINS2, COX4NB and NUP93). Other known breast cancer gene target such as ERBB2, E2F1 and MTDH are in the global driver list. Many of them such as aurora kinases AURKA and survivin (BIRC5) have been targets for anticancer drugs [38–40].
To access the robustness of predicted key drivers, we performed the KDA on the networks (named as the 3N networks) as combinations of any three of the four Bayesian networks. Over 79% of the drivers based on the 3N networks are the drivers based on the combination of all the four BNs. On the other hand, the four driver sets based on the 3N networks significantly overlap with each other (with FET p-values < 1E-14) and they share at least 41% of their members. Therefore, the drivers uncovered are fairly robust. It is of note that the network based on all the four networks leads to many more drivers than any 3N network, indicating the great advantage of the combination of all the networks.
Validation of key drivers via in vitro siRNA knockdown experiments
We assessed the effect of knocking down the genes located on the amplified recurrent ICNV regions by siRNA on breast cancer cell viability because they were enriched for gene sets involved in cell cycle and metabolic regulation. In the previously described siRNA experiments, the median of the viability of the siRNA transfected cells was 64.30%, with a standard deviation of 15.28%, compared to the control cells transfected with an siRNA to luciferase. We used a viability cutoff value of 41.38% (1.5× standard deviation below the median) to determine viability signature genes that, when silenced, significantly decrease cell viability. This resulted in the identification of a 216 gene signature (V1) with a significant effect on cell viability in multiple cell lines. Based on a cutoff of 1.5× standard deviation below the median, we also derived a signature for each cell line. The four signatures from individual cell lines were then combined with V1 to derive a combined signature V2 with 484 genes. The genes in V1 and V2 and their viability scores are shown in Additional File 2, Table S4.
We assessed whether V1 and V2 signatures are significantly enriched in different gene sets including the global drivers, the local drivers, the drivers (global and local), the non-driver genes and the genes not on the recurrent regions (nonRR). Figure 5 shows the fold enrichment of each gene set for the siRNA hit signatures V1 and V2. When compared with the genes not on the recurrent ICNV regions, the genes on these regions are about twice (i.e. 2.1 and 1.8 vs. 0.9) more likely to fall into V1 and V2, respectively. Also the global drivers are most likely to be siRNA hits in both V1 and V2, followed by local drivers and non-drivers. For example, the global drivers, the local drivers and the non drivers are 7.8 (P < 5.8e-4), 4.8 (P < 1.9e-2) and 1.97 (P < 2.5e-6) times more likely to overlap with V1, respectively than the genes on the human genome. When the genes on the recurrent ICNV regions were considered as background, the global drivers were 4.2 (P < 0.0055) and 3.5 (P < 0.003) times more likely to be in V1 and V2, respectively, and the local drivers are less significantly enriched for the signatures.
As mentioned earlier, AURKA and TPX2 are the top key regulators of the recurrent ICNV regions. On the other hand, 107 of the genes on the recurrent regions overlapped with V2 and they include TACC3, ECT2, CDC6, NOTCH1, and PIK3CA etc. Here we found a molecular mechanism that linked TACC3 and TPX2 through AURKA. TACC3, located on an amplified region on 4p16, recently emerged as an important gene in the stabilization of the mitotic spindle, and is up-regulated in several cancer cell lines including thyroid and lung cancers[42–44]. Cell viability was reduced by 59.80% in the TACC3 siRNA transfected cells. AURKA resides on 20q13, which was also identified as a recurrent region of amplification. It has previously been shown that TPX2 is one of several activators for AURKA, which in turn controls the localization of TACC3 to the spindles . Furthermore, TPX2 acts as an allosteric activator of Aurora A, and together they inhibit the activity of tumor suppressor p53 in Xenopus Oocytes (Pascreau et al. 2009). The molecular interaction between the hubs located on different recurrent regions might suggest the trans-association between regions. We expect more mechanisms of this kind will be unraveled through the integration of WACE and network analysis.
These experimental results demonstrate the importance of the recurrent ICNV regions and the predicted key driver genes, especially global drivers in terms of significant impact on cancer cell viability, and thus validate our procedures for inferring CNV regions and identifying cancer driver genes in these inferred CNV regions.
We developed a novel Wavelet based algorithm to Analyze Copy number alteration based on Expression (WACE) and further combined this analysis with gene regulatory network analysis to identify the cancer driver genes in the chromosome regions with genomic alterations. The performance of these two methods was evaluated in Additional File 1, Section 2. In brief, WACE improved on the state-of-the-art algorithm (GACE) by (i) reducing the over-smoothing effect of the Gaussian transform and retaining the local patterns, and (ii) eliminating the type I and II errors induced by the non-zero centered null distribution (Additional File 1, Figure S2). WACE demonstrated superior performance over GACE on several large scale gene expression datasets (see Additional File 1, Section 2). By analyzing multiple datasets, we were able to identify recurrent ICNVs that harbor many cancer-related genes, suggesting genes in these regions are worthy of further study.
Integration of the recurrent regions identified by WACE and the gene regulatory network analysis uncovered not only many well-known oncogenes like BIRC5 and E2F1, but also a number of novel cancer susceptibility genes such as ECT2, TPX2 and TACC3, which are involved in cell cycle and ECM regulation. Many of the cancer driver genes we predicted were subsequently validated via siRNA experiments. Table S5 in Additional File 1 includes the four known and 45 novel breast cancer genes that are in the recurrent regions of amplification and validated by the siRNA experiments across multiple breast cancer cell lines.
The importance of the identified recurrent regions of amplification (ARR) and the inferred drivers are further justified by another independent dataset from Cancer Gene Census http://www.sanger.ac.uk/genetics/CGP/Census/. Among the 19 known breast cancer genes compiled by Cancer Gene Census, 5 are located in the ARRs while 14 are outside the ARRs, indicating that the known breast cancer driver genes are 3.5-fold overrepresented in the ARRs when compared to the genes not on these regions. Among the 5 census genes located in the ARRs, one (ERBB2) is the global key driver and the rest four are not the drivers, representing 25- and 2-fold enrichments, respectively, compared to randomly selected human genes.
There are multiple molecular factors contributing to poor outcome, including cell proliferation, metastasis and cell stemness etc. Our assumption is that CNV significantly contributes to the disease outcome though the separation of the samples into good and bad outcome groups tends to identify metastasis genes. We don't need to pre-specify through what molecular mechanism that CNV drives disease outcome, which can be inferred in a data-driven manner. To further understand the functions of the ARRs, we performed gene co-expression network analysis[47, 48] on the four breast cancer datasets to identify gene modules (comprised of highly interacted genes). A module enriched for cell cycle genes (named as cell cycle module) and conserved across the four corresponding networks is most predictive of survival in all the four studies, indicating cell proliferation contributes to breast cancer outcome. The ARRs are highly enriched for the genes of the cell cycle module (P < 1.2e-14). This is further supported by the fact that the inferred key drivers include not only known breast cancer metastasis genes (MTDH and ERBB2) but also known cancer cell cycle genes such as TPX2, AURKA, E2F1 and BIRC5. As shown in Figure 6, these known cell cycle and metastasis genes interact with each other and with many other drivers to co-regulate the genes on the AARs. Furthermore, AARs are enriched (2.3 fold-enrichment, P < 2.6e-2) for a cell cycle prognostic signature identified as metastasis markers, and two (AURKA and BIRC5) of the thirty-three signature genes are the global key drivers (32 fold-enrichment, P < 1.8e-3). Therefore, cell viability assay, used to test cell proliferation, at least partially validated our drivers. The future experiments will consider cell mobility assay to test how these inferred key drivers impact cancer cell mobility that drives metastasis.
A recent paper by Akavia et al. describes a method to predict cancer driver genes by integrating CNA and gene expression data. Akavia et al's approach bears certain similarity as ours. Both approaches first define gene groups of interest, then identify genes in the groups with cis-CNV as candidate driver genes. As we discussed in the main text, expression levels of genes in the same CNV segments are likely to be correlated so that they are assigned into the group. Candidate genes (with cis-CNV) in the same co-expression module are equivalent so that we cannot rank which candidate genes are more likely to be drivers. Akavia et al. used a literature based method to rank candidate genes. Basically, they chose genes with known connections to cancers. However, our approach is completely data driven. We first constructed causal networks to dissect how genes in the regions of interest are regulated and related to each other and then we ranked candidate genes based on the causal networks, which is the key driver analysis described in the main text. As we mentioned in the previous discussion, majority of the drivers identified by our approach are novel and thus they won't be picked up by Akavia et al's literature based approach.
Jornsten et al. recently developed the EPoC method to integrate CNA and gene expression variations. EPoC focuses on CNA driving gene expression changes but disregards the indirect changes through more hubs. Only genes with CNA can be cancer driver genes based on the EPoC model. However, our Bayesian network approach focuses on how genes are causally related to each other. In our case, predicted cancer driver genes may or may not have copy number alterations. Theoretically, the EPoC method can also derive gene-gene relationship as Jorsten et al. indicated that gene-gene relationship matrix A is the inversion of the CNA-gene relationship matrix G(G= A-1). However, they showed that there was no prediction power using the A matrix. One reason is that in their Lesso formulation for G matrix, they explicitly assumed CNAs are hubs so that G-1 is not exactly A. We have showed that gene-gene networks based on our Bayesian network approach have prediction power[24–27]. Thus, our method can be complimentary to the EPoC method.
The impact of CNV on gene expression has been extensively studied[53, 54]. In our analysis, we focused on genes with cis-regulated CNVs. CNVs may result partial deletions of genes and the functional changes of the affected genes in turn cause expression changes of downstream genes. Gene regulatory networks may be able to capture the effect of these cis-regulated CNVs on the trans-regulated ones. In our model, we explicitly assume CNVs cause gene expression changes. There are many mechanisms that CNV can be arisen. It is possible that expression changes of genes in DNA repair processes affect CNV. More sophisticated causal models, such as dynamic Bayesian network, are needed to capture these causal relationships. It is of note that there is a limitation of this transcriptome-based approach. We may miss kinases or enzymes that drive cancer progression and metastasis if these kinases' or enzymes' activity changes are mainly due to protein level changes. Complementary proteomic approaches are needed to complement this approach.
The framework where the wavelet analysis of copy number alteration based on expression coupled with the gene regulatory network analysis, provides a blueprint for leveraging genomic data to identify key regulatory components and gene targets. To our knowledge, this is the first effort to systematically identify and validate drivers for expression based CNV regions in breast cancer. This integrative approach can be applied to many other large-scale gene expression studies and other novel types of cancer data such as next-generation sequencing based expression (RNA-Seq) as well as CNV data.
This study was funded in part by Merck & Co.
- Hebbring SJ, Moyer AM, Weinshilboum RM: Sulfotransferase gene copy number variation: pharmacogenetics and function. Cytogenet Genome Res. 2008, 123 (1-4): 205-10. 10.1159/000184710View ArticlePubMedGoogle Scholar
- Mullighan CG, Downing JR: Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions. Leukemia. 2009,Google Scholar
- Overdevest JB, Theodorescu D, Lee JK: Utilizing the molecular gateway: the path to personalized cancer management. Clin Chem. 2009, 55 (4): 684-971. 10.1373/clinchem.2008.118554PubMed CentralView ArticlePubMedGoogle Scholar
- Swanton C, Caldas C: Molecular classification of solid tumours: towards pathway-driven therapeutics. Br J Cancer. 2009,Google Scholar
- van 't Veer LJ, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, 415 (6871): 530-6. 10.1038/415530aView ArticlePubMedGoogle Scholar
- Wang Y, et al.: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005, 365 (9460): 671-9.View ArticlePubMedGoogle Scholar
- Fan C, et al.: Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006, 355 (6): 560-9. 10.1056/NEJMoa052933View ArticlePubMedGoogle Scholar
- Sotiriou C, et al.: Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006, 98 (4): 262-72. 10.1093/jnci/djj052View ArticlePubMedGoogle Scholar
- Andre F, et al.: Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res. 2009, 15 (2): 441-51. 10.1158/1078-0432.CCR-08-1791View ArticlePubMedGoogle Scholar
- Haverty PM, et al.: High-resolution genomic and expression analyses of copy number alterations in breast tumors. Genes Chromosomes Cancer. 2008, 47 (6): 530-42. 10.1002/gcc.20558View ArticlePubMedGoogle Scholar
- Heidenblad M, et al.: Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic amplifications. Oncogene. 2005, 24 (10): 1794-801. 10.1038/sj.onc.1208383View ArticlePubMedGoogle Scholar
- Pollack JR, et al.: Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA. 2002, 99 (20): 12963-8. 10.1073/pnas.162471999PubMed CentralView ArticlePubMedGoogle Scholar
- Hu G, et al.: MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell. 2009, 15 (1): 9-20. 10.1016/j.ccr.2008.11.013PubMed CentralView ArticlePubMedGoogle Scholar
- van 't Veer LJ, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, 415 (6871): 530-6. 10.1038/415530aView ArticlePubMedGoogle Scholar
- Miller LD, et al.: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA. 2005, 102 (38): 13550-5. 10.1073/pnas.0506230102PubMed CentralView ArticlePubMedGoogle Scholar
- Bergamaschi A, et al.: Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer. 2006, 45 (11): 1033-40. 10.1002/gcc.20366View ArticlePubMedGoogle Scholar
- Stratton MR, Campbell PJ, Futreal PA: The cancer genome. Nature. 2009, 458 (7239): 719-24. 10.1038/nature07943PubMed CentralView ArticlePubMedGoogle Scholar
- Torkamani A, et al.: Coexpression network analysis of neural tissue reveals perturbations in developmental processes in schizophrenia. Genome Res. 2010, 20 (4): 403-12. 10.1101/gr.101956.109PubMed CentralView ArticlePubMedGoogle Scholar
- Cerami E, et al.: Automated network analysis identifies core pathways in glioblastoma. PLoS ONE. 2010, 5 (2): e8918- 10.1371/journal.pone.0008918PubMed CentralView ArticlePubMedGoogle Scholar
- Kulp DC, Jagalur M: Causal inference of regulator-target pairs by gene mapping of expression phenotypes. BMC Genomics. 2006, 7: 125- 10.1186/1471-2164-7-125PubMed CentralView ArticlePubMedGoogle Scholar
- Lum PY, et al.: Elucidating the murine brain transcriptional network in a segregating mouse population to identify core functional modules for obesity and diabetes. J Neurochem. 2006, 97 (Suppl 1): 50-62.View ArticlePubMedGoogle Scholar
- Mehrabian M, et al.: Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits. Nat Genet. 2005, 37 (11): 1224-33. 10.1038/ng1619View ArticlePubMedGoogle Scholar
- Schadt EE, et al.: An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet. 2005, 37 (7): 710-7. 10.1038/ng1589PubMed CentralView ArticlePubMedGoogle Scholar
- Zhu J, et al.: An integrative genomics approach to the reconstruction of gene networks in segregating populations. Cytogenet Genome Res. 2004, 105 (2-4): 363-74. 10.1159/000078209View ArticlePubMedGoogle Scholar
- Zhu J, et al.: Integrating large-scale functional genomic data to dissect the complexity of yeast regulatory networks. Nat Genet. 2008, 40 (7): 854-61. 10.1038/ng.167PubMed CentralView ArticlePubMedGoogle Scholar
- Zhu J, et al.: Increasing the Power to Detect Causal Associations by Combining Genotypic and Expression Data in Segregating Populations. PLoS Comput Biol. 2007, 3 (4): e69- 10.1371/journal.pcbi.0030069PubMed CentralView ArticlePubMedGoogle Scholar
- Yang X, et al.: Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res. 2010,Google Scholar
- Sharan R, Ulitsky I, Shamir R: Network-based prediction of protein function. Mol Syst Biol. 2007, 3: 88-PubMed CentralView ArticlePubMedGoogle Scholar
- Roodi N, et al.: Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst. 1995, 87 (6): 446-51. 10.1093/jnci/87.6.446View ArticlePubMedGoogle Scholar
- Bartz SR, et al.: Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol. 2006, 26 (24): 9377-86. 10.1128/MCB.01229-06PubMed CentralView ArticlePubMedGoogle Scholar
- Berns K, et al.: A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature. 2004, 428 (6981): 431-7. 10.1038/nature02371View ArticlePubMedGoogle Scholar
- Jackson AL, et al.: Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol. 2003, 21 (6): 635-7. 10.1038/nbt831View ArticlePubMedGoogle Scholar
- Strang GN, Truong : Wavelets and Filter Banks. 1996, Wellesley, MA, USA: Wellesley-Cambrage Press,Google Scholar
- Boulay PL, et al.: ADP-ribosylation factor 1 controls the activation of the phosphatidylinositol 3-kinase pathway to regulate epidermal growth factor-dependent growth and migration of breast cancer cells. J Biol Chem. 2008, 283 (52): 36425-34. 10.1074/jbc.M803603200PubMed CentralView ArticlePubMedGoogle Scholar
- Lu X, et al.: In vivo dynamics and distinct functions of hypoxia in primary tumor growth and organotropic metastasis of breast cancer. Cancer Res. 2010, 70 (10): 3905-14. 10.1158/0008-5472.CAN-09-3739PubMed CentralView ArticlePubMedGoogle Scholar
- Nakshatri H, Badve S: FOXA1 in breast cancer. Expert Rev Mol Med. 2009, 11: e8-View ArticlePubMedGoogle Scholar
- Torkamani A, Schork NJ: Identification of rare cancer driver mutations by network reconstruction. Genome Res. 2009, 19 (9): 1570-8. 10.1101/gr.092833.109PubMed CentralView ArticlePubMedGoogle Scholar
- Macarulla T, Ramos FJ, Tabernero J: Aurora kinase family: a new target for anticancer drug. Recent Pat Anticancer Drug Discov. 2008, 3 (2): 114-22. 10.2174/157489208784638785View ArticlePubMedGoogle Scholar
- Mita AC, et al.: Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008, 14 (16): 5000-5. 10.1158/1078-0432.CCR-08-0746View ArticlePubMedGoogle Scholar
- Rana S, et al.: Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther. 2008, 8 (9): 1461-70. 10.1586/14737188.8.131.521View ArticlePubMedGoogle Scholar
- Peset I, Vernos I: The TACC proteins: TACC-ling microtubule dynamics and centrosome function. Trends Cell Biol. 2008, 18 (8): 379-88. 10.1016/j.tcb.2008.06.005View ArticlePubMedGoogle Scholar
- Fridlyand J, et al.: Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer. 2006, 6: 96- 10.1186/1471-2407-6-96PubMed CentralView ArticlePubMedGoogle Scholar
- Still IH, Vince P, Cowell JK: The third member of the transforming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell lines. Genomics. 1999, 58 (2): 165-70. 10.1006/geno.1999.5829View ArticlePubMedGoogle Scholar
- Ulisse S, et al.: Transforming acidic coiled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues. Endocr Relat Cancer. 2007, 14 (3): 827-37. 10.1677/ERC-07-0053PubMed CentralView ArticlePubMedGoogle Scholar
- Kufer TA, et al.: Human TPX2 is required for targeting Aurora-A kinase to the spindle. J Cell Biol. 2002, 158 (4): 617-23. 10.1083/jcb.200204155PubMed CentralView ArticlePubMedGoogle Scholar
- LeRoy PJ, et al.: Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: a novel pharmacodynamic method for measuring Aurora A activity. Cancer Res. 2007, 67 (11): 5362-70. 10.1158/0008-5472.CAN-07-0122View ArticlePubMedGoogle Scholar
- Emilsson V, et al.: Genetics of gene expression and its effect on disease. Nature. 2008, 452 (7186): 423-8. 10.1038/nature06758View ArticlePubMedGoogle Scholar
- Zhang B, Horvath S: A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol. 2005, 4: Article17,Google Scholar
- Xu X, et al.: Quantitative proteomics study of breast cancer cell lines isolated from a single patient: discovery of TIMM17A as a marker for breast cancer. Proteomics. 2010, 10 (7): 1374-90. 10.1002/pmic.200900380View ArticlePubMedGoogle Scholar
- Li J, et al.: Identification of high-quality cancer prognostic markers and metastasis network modules. Nat Commun. 2010, 1: 34-PubMedGoogle Scholar
- Akavia UD, et al.: An integrated approach to uncover drivers of cancer. Cell. 2010, 143 (6): 1005-17. 10.1016/j.cell.2010.11.013PubMed CentralView ArticlePubMedGoogle Scholar
- Jornsten R, et al.: Network modeling of the transcriptional effects of copy number aberrations in glioblastoma. Mol Syst Biol. 2011, 7: 486-PubMed CentralView ArticlePubMedGoogle Scholar
- Cahan P, et al.: The impact of copy number variation on local gene expression in mouse hematopoietic stem and progenitor cells. Nat Genet. 2009, 41 (4): 430-7. 10.1038/ng.350PubMed CentralView ArticlePubMedGoogle Scholar
- Stranger BE, et al.: Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science. 2007, 315 (5813): 848-53. 10.1126/science.1136678PubMed CentralView ArticlePubMedGoogle Scholar
- Hastings PJ, et al.: Mechanisms of change in gene copy number. Nat Rev Genet. 2009, 10 (8): 551-64. 10.1038/nrg2593PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.